Filing Details

Accession Number:
0000899243-18-020579
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-07-25 16:17:17
Reporting Period:
2018-07-23
Accepted Time:
2018-07-25 16:17:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1552451 Myokardia Inc MYOK Pharmaceutical Preparations (2834) 455500552
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1654909 Jake Bauer C/O Myokardia, Inc.
333 Allerton Avenue
South San Francisco CA 94080
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-07-23 7,500 $13.90 68,106 No 4 M Direct
Common Stock Disposition 2018-07-23 4,399 $56.59 63,707 No 4 S Direct
Common Stock Disposition 2018-07-23 3,101 $57.28 60,606 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-07-23 7,500 $0.00 7,500 $13.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,500 2027-07-19 No 4 M Direct
Footnotes
  1. This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. Represents the weighted average sale price of the shares sold ranging from $56.00 to $56.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  3. Represents the weighted average sale price of the shares sold ranging from $57.00 to $57.60 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  4. The shares subject to this option vest and become exercisable in in two annual installments after July 20, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date.